[go: up one dir, main page]

WO2005040819A1 - Diagnostics et traitements de maladies associees a un transporteur d'ion organique de type cerebral puissant boct (boct) - Google Patents

Diagnostics et traitements de maladies associees a un transporteur d'ion organique de type cerebral puissant boct (boct) Download PDF

Info

Publication number
WO2005040819A1
WO2005040819A1 PCT/EP2004/011014 EP2004011014W WO2005040819A1 WO 2005040819 A1 WO2005040819 A1 WO 2005040819A1 EP 2004011014 W EP2004011014 W EP 2004011014W WO 2005040819 A1 WO2005040819 A1 WO 2005040819A1
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
boct
polypeptide
cancer
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/011014
Other languages
English (en)
Inventor
Stefan Golz
Ulf Brüggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2005040819A1 publication Critical patent/WO2005040819A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/5753—
    • G01N33/57515—
    • G01N33/5752—
    • G01N33/57545—
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • a “signal sequence” or “leader sequence” can be used, when desired, to direct the polypeptide through a membrane of a cell.
  • Such a sequence may be naturally present on the polypeptides of the present invention or provided from heterologous sources by recombinant DNA techniques.
  • QC-PCR quantitative competitive PCR
  • An internal control competitor in each reaction [Piatak, (1993), BioTech ⁇ iques].
  • the efficiency of each reaction is normalized to the internal competitor.
  • a known amount of internal competitor is typically added to each sample.
  • the unknown target PCR product is compared with the known competitor PCR product to obtain relative quantitation.
  • a difficulty with this general approach lies in developing an internal control that amplifies with the same efficiency than the target molecule.
  • One detector which is specifically adapted for measuring fluorescence emissions such as those created during a fluorogenic assay is the ABI 7700 or 4700 HT manufactured by Applied Biosystems, Inc. in Foster City, Calif.
  • the ABI 7700 uses fiber optics connected with each well in a 96-or 384 well PCR tube arrangement.
  • the instrument includes a laser for exciting the labels and is capable of measuring the fluorescence spectra intensity from each tube with continuous monitoring during PCR amplification. Each tube is re-examined every 8.5 seconds.
  • a variety of expression vector/host systems can be utilized to contain and express sequences encoding BOCT. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (e.g., baculovirus), plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors
  • yeast transformed with yeast expression vectors insect cell systems infected with virus expression vectors (e.g., baculovirus)
  • plant cell systems transformed with virus expression vectors e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus
  • ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art.
  • the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme.
  • the hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target RNA.
  • Liver diseases comprise primary or secondary, acute or chronic diseases or injury of the liver which may be acquired or inherited, benign or malignant, and which may affect the liver or the body as a whole. They comprise but are not limited to disorders of the bilirubin metabolism, jaundice, syndroms of Gilbert's, Crigler-Najjar, Dubin-Johnson and Rotor; intrahepatic cholestasis, hepatomegaly, portal hypertension, ascites, Budd-Chiari syndrome, portal-systemic encephalopathy, fatty liver, steatosis, Reye's syndrome, liver diseases due to alcohol, alcoholic hepatitis or cirrhosis, fibrosis and cirrhosis, fibrosis and cirrhosis of the liver due to inborn errors of metabolism or exogenous substances, storage diseases, syndromes of Gaucher's, Zellweger's, Wilson's - disease, acute or chronic hepatitis, viral hepatitis and its variants,
  • Other resident cells such as smooth muscle cells, lung epithelial cells, mucus-producing cells, and nerve cells may also be abnormal in individuals with asthma and may contribute to its pathology. While the airway obstruction of asthma, presenting clinically as an intermittent wheeze and shortness of breath, is generally the most pressing symptom of the disease requiring immediate treatment, the inflammation and tissue destruction associated with the disease can lead to irreversible changes that eventually make asthma a chronic and disabling disorder requiring long-term management.
  • the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
  • suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
  • retention enemas for rectal delivery.
  • Normal dosage amounts can vary from 0.1 micrograms to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration.
  • Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.
  • the degree of homology can readily be calculated by known methods. Preferred methods to determine homology are designed to give the largest match between the sequences tested. Methods to determine homology are codified in publicly available computer programs such as BestFit, BLASTP, BLASTN, and FASTA. The BLAST programs are publicly available from NCBI and other sources in the internet.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un BOCT humain associé à des maladies cardiovasculaires, à des maladies endocrinologiques, à des maladies métaboliques, à des cancers, à des inflammations, à des maladies gastroentérologiques, à des maladies hématologiques, à des maladies urologiques et à des maladies respiratoires. L'invention concerne également des dosages destinés à identifier des composés utiles dans le traitement ou la prévention de maladies cardiovasculaires, de maladies endocrinologiques, de maladies métaboliques, de cancers, d'inflammations, de maladies gastroentérologiques, de maladies hématologiques, de maladies urologiques et de maladies respiratoires. Cette invention concerne aussi des composés qui se lient et/ou activent ou inhibent l'activité de BOCT, ainsi que des compositions pharmaceutiques contenant ces composés.
PCT/EP2004/011014 2003-10-17 2004-10-02 Diagnostics et traitements de maladies associees a un transporteur d'ion organique de type cerebral puissant boct (boct) Ceased WO2005040819A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03023811 2003-10-17
EP03023811.7 2003-10-17

Publications (1)

Publication Number Publication Date
WO2005040819A1 true WO2005040819A1 (fr) 2005-05-06

Family

ID=34486078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/011014 Ceased WO2005040819A1 (fr) 2003-10-17 2004-10-02 Diagnostics et traitements de maladies associees a un transporteur d'ion organique de type cerebral puissant boct (boct)

Country Status (1)

Country Link
WO (1) WO2005040819A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041684A3 (fr) * 2005-10-04 2008-01-17 Forsyth Inst Flux ionique dans des processus biologiques et procedes associes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024610A1 (fr) * 1997-11-06 1999-05-20 Millennium Pharmaceuticals, Inc. Genes codant pour des molecules transporteuses
DE19937846A1 (de) * 1999-08-13 2001-02-15 Michael Brues h BOCT: Gen, cDNA, Expression, Aminosäuresequenz
EP1092725A1 (fr) * 1998-07-02 2001-04-18 Taisho Pharmaceutical Co., Ltd Transporteur de saccharides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024610A1 (fr) * 1997-11-06 1999-05-20 Millennium Pharmaceuticals, Inc. Genes codant pour des molecules transporteuses
EP1092725A1 (fr) * 1998-07-02 2001-04-18 Taisho Pharmaceutical Co., Ltd Transporteur de saccharides
DE19937846A1 (de) * 1999-08-13 2001-02-15 Michael Brues h BOCT: Gen, cDNA, Expression, Aminosäuresequenz

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041684A3 (fr) * 2005-10-04 2008-01-17 Forsyth Inst Flux ionique dans des processus biologiques et procedes associes

Similar Documents

Publication Publication Date Title
WO2004097421A2 (fr) Diagnostics et traitements destines a des maladies associees au recepteur de type recepteur calcitonine (calcrl)
US20080038247A1 (en) Diagnostics and Therapeutics for Diseases Associated With G-Protein-Coupled Receptor Gpr39 (Gpr39)
US20070105104A1 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2005054848A2 (fr) Diagnostics et therapeutique pour maladies associees au canal potassique a rectification entrante couple a une proteine (girk2)
WO2006005471A1 (fr) Diagnostic et traitement de maladies associees au recepteur vanilloide 2 (vr2(vrl-1))
WO2006021343A2 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005076007A2 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2005040819A1 (fr) Diagnostics et traitements de maladies associees a un transporteur d'ion organique de type cerebral puissant boct (boct)
WO2005047905A1 (fr) Diagnostic et therapie de maladies associees au recepteur 22 couple a la proteine g (gpr22)
WO2005052586A2 (fr) Elements de diagnostic et de therapie pour des maladies associees au canal potassique, sous famille k et element 3 (kcnk3)
WO2005040830A1 (fr) Agents de diagnostic et de traitement des maladies associees au transporteur 3 de cations organiques (orctl3)
WO2005026724A2 (fr) Substances pour diagnostic et traitement d'affections associees au transporteur de cations organiques slc22a5
WO2005075510A1 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au canal potassique, agents membres 9 de la sous-famille k (kcnk9)
US20070059694A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep1 (prostaglandin e2 ep1)
WO2005101011A2 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2004073587A2 (fr) Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1)
WO2005095984A2 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2005026723A1 (fr) Diagnostiques et procedes therapeutiques pour des maladies associees au transporteur slc22a1 de cations organiques (slc22a1)
WO2005026726A1 (fr) Agents diagnostiques et therapeutiques pour maladies associees au transporteur de cations organiques slc22a7
WO2005080973A1 (fr) Diagnostic et traitement de maladies associees au recepteur nucleaire humain nr5a1 (nr5a1)
WO2004074830A2 (fr) Diagnostics et therapies de maladies associees au recepteur de la prostaglandine e2 ep3 iii (prostaglandine e2 ep3 iii) lie a la proteine g
WO2005078455A1 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur humain de la melatonine de type 1a (mtnr1a)
WO2005040789A2 (fr) Diagnostics et traitements de maladies associees a un transporteur d'ion organique putatif okb1 (okb1)
WO2005054867A2 (fr) Diagnostics et therapeutique pour maladies associees au canal potassique de la sous-famille k, membre 5 (kcnk5)
WO2006021347A2 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 3c de 5-hydroxytryptamine (5-ht3c)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase